GL1X · GenesisL1 explorer

MolNFT v1 · #105876 · protein

Crystal structure of dccd-modified psbs from spinach

4RI3 · Photosystem II 22 kda protein, chloroplastic: “Crystal structure of dccd-modified psbs from spinach”. X-ray diffraction, 3 ligands (BNG, DCW, HG), 1 pocket (best druggability 0.76). MolNFT v1 #105876 on GenesisL1: 3D structure…

PDB
4RI3
Type
protein
Length
336 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Photosystem II 22 kda protein, chloroplastic
UniProt
Q02060
Ligands
BNG, DCW, HG
Pockets
1 · best druggability 0.76

Structure

x-ray diffraction · 2 distinct chains · 60% helix, 7% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
APhotosystem II 22 kda protein, chloroplasticprotein17459% helix, 6% strandQ02060
BPhotosystem II 22 kda protein, chloroplasticprotein16262% helix, 8% strandQ02060

Ligands and binding sites

  • BNG · nonyl beta-D-glucopyranoside · ligand · 4 copies · chains A, B
  • DCW · Dicyclohexylurea · ligand · 2 copies · chains A, B
  • HG · Mercury (II) ion · metal · 7 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

1 pocket found on a 1 Å grid, 1 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
111870.760.7771DCW

Interfaces

1 interface between chains.

  • A–B · 1697 Ų buried · 24 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 covalent (covalent ligand).

Compared structures

  • 4RI3 · Crystal structure of DCCD-modified PsbS from spinach · the same entry in another collection · chain A against A, TM-score 1.00
  • Q02060 · AlphaFold monomer V2.0 prediction for photosystem II 22 kda protein, chloroplastic… · a predicted model of the same protein · chain B against A, TM-score 0.99

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.